Abstract
Management of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is puzzling, and therapeutic choices can be complicated, due to both wide genetic heterogeneity and protean clinical phenotype. We report on a 35-year-old female who was diagnosed with TRAPS, after finding the V95M mutation on the TNFRSF1A gene; who was treated in order with etanercept, anakinra, and canakinumab (150 mg/every 8 weeks by subcutaneous injection, then increased to 150 mg every 4 weeks); and who started therapy with oral alendronate (70 mg/weekly) to control her osteoporosis. Alendronate combined with canakinumab led to the optimal clinical control of all TRAPS manifestations and normalization of inflammatory markers. Further studies should be performed to clarify bisphosphonates’ role in the scenery of autoinflammatory disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144
Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43
Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707
Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847
Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908
Romas E, Gillespie MT (2006) Inflammation-induced bone loss: can it be prevented? Rheum Dis Clin N Am 32:759–773
Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A (2007) Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 109:2416–2418
Cantatore FP, Introsso AM, Carrozzo M (1996) Effects of bisphosphonates on interleukin 1, tumor necrosis factor alpha, and beta 2 microglobulin in rheumatoid arthritis. J Rheumatol 23:1117–1118
Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V et al (1995) Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10:1719–1725
Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.12.002
Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B, Galeazzi M, Rigante D (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196
Disclosures
Luca Cantarini received grant/research support from Novartis and SOBI and is a consultant for Novartis and SOBI.
Author information
Authors and Affiliations
Corresponding author
Additional information
Giuseppe Lopalco and Donato Rigante equally contributed to this manuscript.
Rights and permissions
About this article
Cite this article
Lopalco, G., Rigante, D., Vitale, A. et al. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol 34, 807–809 (2015). https://doi.org/10.1007/s10067-014-2556-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2556-8